The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who are at high risk of becoming seriously ill. It will also require manufacturers to conduct clinical trials to show whether the vaccines benefit healthy younger adults and children.

The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for healthy individuals under 65. This decision contrasts with previous recommendations for annual shots for all.

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.

Health-related headlines include Mexico's suspension of poultry imports from Brazil due to bird flu, promising results from new HIV vaccine trials, and the FDA's conditional approval of Novavax's COVID-19 vaccine.

Coinbase Global (COIN) will begin trading on the S&P 500 (^GSPC) effective today, replacing Discover Financial Services (DFS) on the exchange. The US Food and Drug Administration (FDA) approves Novavax's (NVAX) COVID-19 vaccine,